Kiora Pharmaceuticals (KPRX) Competitors $3.17 +0.22 (+7.46%) Closing price 03/5/2025 04:00 PM EasternExtended Trading$3.08 -0.09 (-3.00%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KPRX vs. SCYX, RAPT, CLNN, GBIO, ESLA, GRCE, CASI, OVID, INKT, and SRZNShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include SCYNEXIS (SCYX), RAPT Therapeutics (RAPT), Clene (CLNN), Generation Bio (GBIO), Estrella Immunopharma (ESLA), Grace Therapeutics (GRCE), CASI Pharmaceuticals (CASI), Ovid Therapeutics (OVID), MiNK Therapeutics (INKT), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. SCYNEXIS RAPT Therapeutics Clene Generation Bio Estrella Immunopharma Grace Therapeutics CASI Pharmaceuticals Ovid Therapeutics MiNK Therapeutics Surrozen SCYNEXIS (NASDAQ:SCYX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking. Which has more volatility and risk, SCYX or KPRX? SCYNEXIS has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500. Is SCYX or KPRX more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. Kiora Pharmaceuticals' return on equity of 21.32% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-425.41% -66.21% -38.84% Kiora Pharmaceuticals N/A 21.32%16.39% Do analysts rate SCYX or KPRX? Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 215.46%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals have more ownership in SCYX or KPRX? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by company insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor SCYX or KPRX? In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 0.62 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Very Positive Kiora Pharmaceuticals Positive Which has better valuation and earnings, SCYX or KPRX? SCYNEXIS has higher earnings, but lower revenue than Kiora Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$8.57M4.40$67.04M-$0.74-1.34Kiora Pharmaceuticals$16M0.59-$12.51MN/AN/A Does the MarketBeat Community believe in SCYX or KPRX? SCYNEXIS received 488 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 73.91% of users gave Kiora Pharmaceuticals an outperform vote while only 70.04% of users gave SCYNEXIS an outperform vote. CompanyUnderperformOutperformSCYNEXISOutperform Votes50570.04% Underperform Votes21629.96% Kiora PharmaceuticalsOutperform Votes1773.91% Underperform Votes626.09% SummaryKiora Pharmaceuticals beats SCYNEXIS on 10 of the 16 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.51M$7.26B$5.85B$8.48BDividend YieldN/A2.78%4.89%3.98%P/E RatioN/A6.1925.1719.37Price / Sales0.59225.94387.71116.92Price / CashN/A65.6738.0534.62Price / Book0.446.537.364.33Net Income-$12.51M$138.98M$3.18B$246.62M7 Day Performance-6.21%-1.64%-2.20%-3.05%1 Month Performance-16.36%-8.91%-6.88%-6.50%1 Year Performance-47.35%-11.39%14.29%5.95% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.7952 of 5 stars$3.17+7.5%$10.00+215.5%-47.4%$9.51M$16M0.0010SCYXSCYNEXIS0.9196 of 5 stars$0.97-5.8%N/A-39.9%$36.81M$8.57M-1.3160Positive NewsRAPTRAPT Therapeutics4.1053 of 5 stars$1.05-7.9%$5.29+403.4%-87.0%$36.71M$1.53M-0.3880CLNNClene3.1019 of 5 stars$4.33-3.8%$55.25+1,176.0%-41.7%$36.05M$421,000.00-0.82100Upcoming EarningsGBIOGeneration Bio3.1717 of 5 stars$0.54-7.4%$6.50+1,110.2%-81.8%$35.88M$18.58M-0.25150ESLAEstrella Immunopharma3.0887 of 5 stars$0.99-3.9%$16.00+1,516.2%+3.0%$35.82MN/A-3.81N/ANews CoveragePositive NewsGRCEGrace Therapeutics2.3984 of 5 stars$2.65-12.5%$12.00+352.8%N/A$35.56MN/A-2.28N/ACASICASI Pharmaceuticals4.243 of 5 stars$2.27+0.9%$6.00+164.3%-57.8%$35.17M$22.06M-1.02180Analyst ForecastOVIDOvid Therapeutics4.5844 of 5 stars$0.49-6.9%$4.03+717.6%-84.6%$35.03M$631,695.00-1.0560Gap UpINKTMiNK Therapeutics2.5563 of 5 stars$8.79-1.8%$37.50+326.6%-16.8%$34.84MN/A-2.2530SRZNSurrozen3.4554 of 5 stars$10.70-6.7%$38.50+259.8%-12.2%$34.78M$10M0.0080Positive NewsGap Down Related Companies and Tools Related Companies SCYNEXIS Competitors RAPT Therapeutics Competitors Clene Competitors Generation Bio Competitors Estrella Immunopharma Competitors Grace Therapeutics Competitors CASI Pharmaceuticals Competitors Ovid Therapeutics Competitors MiNK Therapeutics Competitors Surrozen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPRX) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
